Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Nov
13
Today In Oncology
Underlying Mechanisms of Chemoresistance in AML
Exercise Training Improves Strength and Quality of Life for Patients With Metastatic Breast Cancer
Supportive Care: Most Clinic Staff Prefer People-Focused vs Digital Solutions
Addition of Eryaspase to Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma
Longtime FDA Innovator Appointed as Director of CDER
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo